Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.34 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.32 |
| ▸ | DPP4 | P27487 | 2/20 | 0.32 |
| ▸ | DPP7 | Q9UHL4 | 2/20 | 0.32 |
| ▸ | DPP8 | Q6V1X1 | 1/20 | 0.32 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.32 |
| ▸ | GAA | P10253 | 1/20 | 0.32 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4837047 | 0.87 | NPC1 (0.36) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2955527 | 0.84 | GAA (0.43) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL2961336 | 0.83 | ALOX15 (0.52) | ALDH1A1ALOX15AKR1C3SMN1; SMN2 | |
| SCHEMBL2956860 | 0.83 | SPR (0.36) | — | |
| SCHEMBL2958195 | 0.77 | PRMT5 (0.38) | ADORA2AAKR1C3 | |
| SCHEMBL2953694 | 0.77 | LIPE (0.38) | NPC1ALDH1A1MEN1KMT2ASMN1; SMN2 | |
| SCHEMBL1573920 | 0.74 | MAP2K4 (0.41) | NPC1RAB9AALDH1A1MEN1KMT2A | |
| SCHEMBL1573644 | 0.73 | RAB9A (0.39) | NPC1RAB9AALDH1A1SMN1; SMN2HPGD | |
| SCHEMBL4828449 | 0.71 | SPR (0.34) | HPGD | |
| SCHEMBL16242493 | 0.71 | FAAH (0.42) | NPC1RAB9AALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1937648-B1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI SA (FR) | 2014-11-26 | — | — | EP | disclosed |
| US-8357698-B2 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI (FR) | 2013-01-22 | — | — | US | disclosed |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2010-11-11 | — | — | US | disclosed |
| US-7772268-B2 | inhibitors of hormone-sensitive lipase and/or endothelial lipase; for treatment of diabetes mellitus, dyslipidemia and atherosclerotic disorders | SANOFI-AVENTIS (FR) | 2010-08-10 | — | — | US | disclosed |
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | SANOFI-AVENTIS (FR) | 2008-11-20 | — | — | US | disclosed |
| EP-1937648-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | sanofi-aventis (FR) | 2008-07-02 | — | — | EP | disclosed |
| WO-2007042178-A1 | DIACYL INDAZOL DERIVATIVES AS LIPASE AND PHOSPHOLIPASE INHIBITORS | SANOFI-AVENTIS (DE) | 2007-04-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080287448-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | NPC1 1326/4885RAB9A 1832/4885ALDH1A1 959/4885 |
| US-20100286133-A1 | Diacyl indazole derivatives as lipase and phospholipase inhibitors | PNLIP, DAGLA, MGLL | NPC1 1326/4885RAB9A 1832/4885ALDH1A1 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.